Equibles does not estimate personal net worth.
Get an email with a short summary when Neurocrine Biosciences Inc publishes a filing, an earnings call transcript or a press release.
Get NBIX alertsThe proxy statement of Neurocrine Biosciences Inc reports total compensation of $9,007,803 for Sanjay Keswani in fiscal 2025, including a base salary of $379,167. Sanjay Keswani has spoken on 3 earnings calls across 1 company, most recently for Neurocrine Biosciences Inc on July 30, 2026. Neurocrine Biosciences Inc is classified in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. Other leadership on record at Neurocrine Biosciences Inc includes Kevin Gorman (CEO and Board Member), Kyle Gano, Ph.D. (CEO and Board Member), Kyle W. Gano (CEO and Board Member) and 7 others.
“I'll begin today with highlights from Endo 2026, where we presented important new data for both Crenicity and 5CAT-XR. Starting with Crenicity, we presented two-year data from the ongoing Catalyst open-label studies in pediatric and adult patients with classic congenital adrenal hyperplasia.”
“I'd like to begin with highlights from two recent scientific conferences. Firstly, the American Association of Clinical Endocrinology 2026 annual meeting in Las Vegas.”
“In keeping with this year's focus on momentum and strategic diversification, our clinical organization will enroll in advance more studies than at any point in neuroquint history.”
Proxy statement
Start not stated–present
Last confirmed April 15, 2026
Drug Manufacturers - Specialty & Generic · Healthcare
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Neurocrine Biosciences Inc (NBIX) | Chief Medical Officer | $379,167 | $9,007,803 |
